Form 4: Upstream Bio Director Receives Stock Option Grant

Director Marcella K. Ruddy was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Summary

• Director Marcella K. Ruddy received a grant of 17,096 stock options for Upstream Bio, Inc. (UPB) common stock.
• The options have an exercise price of $6.69 per share.
• The grant date for the transaction was June 9, 2026.
• The options are scheduled to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 9, 2027 or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Insider Trading, Stock Options, Director Compensation